Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 6/20 | 1.00 |
| ▸ | SCN2A | Q99250 | 6/20 | 0.81 |
| ▸ | HPGDS | O60760 | 8/20 | 0.79 |
| ▸ | JAK2 | O60674 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17269682 | 1.00 | NPY5R (1.00) | NPY5RSCN2AHPGDSJAK2 | |
| SCHEMBL2174976 | 0.90 | SCN2A (1.00) | NPY5RSCN2AHPGDS | |
| SCHEMBL2315197 | 0.89 | HPGDS (1.00) | NPY5RSCN2AHPGDS | |
| SCHEMBL17283469 | 0.88 | SCN2A (0.96) | NPY5RSCN2AHPGDS | |
| SCHEMBL27815625 | 0.84 | NPY5R (0.87) | NPY5RSCN2AHPGDS | |
| SCHEMBL10773462 | 0.82 | NPY5R (0.70) | NPY5RSCN2AHPGDSJAK2 | |
| SCHEMBL27817123 | 0.80 | SCN2A (0.79) | NPY5RSCN2AHPGDS | |
| SCHEMBL27843962 | 0.80 | SCN2A (0.79) | NPY5RSCN2AHPGDS | |
| SCHEMBL27815623 | 0.80 | SCN2A (0.79) | NPY5RSCN2AHPGDS | |
| SCHEMBL32681493 | 0.79 | SCN2A (0.71) | NPY5RSCN2AHPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8865732-B2 | Heterocyclic compounds and uses thereof | NOVARTIS AG (CH) | 2014-10-21 | — | — | US | disclosed |
| US-20130210818-A1 | Novel Heterocyclic Compounds and Uses Thereof | NOVARTIS AG (CH) | 2013-08-15 | — | — | US | disclosed |
| US-8129394-B2 | Heteroaryl-substituted imidazole compounds and uses thereof | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | NOVARTIS AG (CH) | 2010-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | BRAF, ARAF, KRAS | NPY5R 4815/4885SCN2A 4768/4885HPGDS 1701/4885 |
| US-20130210818-A1 | Novel Heterocyclic Compounds and Uses Thereof | BRAF, RAF1, HRAS | NPY5R 4838/4885SCN2A 4037/4885HPGDS 868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.